The 2023 LCRF-Daiichi Sankyo- AstraZeneca Research Grant on Antibody Drug Conjugates from the Lung Cancer Research Foundation (LCRF) in collaboration with Daiichi Sankyo and AstraZeneca funds innovative projects worldwide focused on antibody drug conjugates (ADCs) to improve outcomes for people with lung cancer.
Projects should be focused on one or more of the following topics that support research studies to develop further understanding of the mechanism of action and biomarkers for TROP2 directed ADCs in lung cancer and HER2 directed ADCs in HER2 mutant NSCLC and primary and acquired resistance to TROP2 directed and HER2 directed ADCs, including:
- Employment of state-of-the art technology to characterize ADC target expression on patient biopsies
- Development and evaluation of patient-derived xenograft models (PDX) from patients responsive and/or resistant to TROP2 directed or HER2 directed ADCs
- Discovery and/or validation of predictive biomarkers of TROP2 directed or HER2 directed ADCs efficacy in the lung cancer
- Prevalence of potential prognostic or predictive biomarkers from lung cancer cells and/or blood
- Co-expression of the identified biomarkers with other known biomarkers (eg actionable drivers, immune-related biomarkers, poor prognosis biomarkers)
- Evolution of the biomarkers pre-, during- and post-SOC treatment
Applicants may be based at universities and research institutions anywhere in the world. Senior investigators with more than 10 years’ experience since faculty appointment are generally not eligible for funding. The grant provides a maximum of 270,000 USD (direct costs only) over a period of two years (disbursed at 135,000 USD per year).
The application deadline has been extended to July 15, 2023.
July 15, 2023